News
August 9, 2004 - Collaboration with Peakdale
Cyprotex and Peakdale Collaborate in ADME Prediction Technology for More Efficient Drug Discovery
Cyprotex (LSE: CRX) and Peakdale Molecular today announce their collaboration in the development of tools to help improve the design of new pharmaceutical compounds.
In the agreement, Cyprotex will use its Cloe Screen™ technology to evaluate the absorption, distribution, metabolism and excretion (ADME) properties of up to 8,500 compounds developed and synthesised by Peakdale. The companies will use the data to develop predictive models that will be used to enhance the design of novel compounds.
Cloe Screen™, Cyprotex's cost-efficient, high throughput screening system, will generate a large and highly consistent data set on Peakdale's compounds which will form a crucial basis for predicting the properties of compounds which have yet to be synthesised. In the drive towards improved productivity within Pharmaceutical and Biotechnology companies, this capability will prove critical since it will help to enhance the ADME profile of compound libraries and provide a better starting point from which to discover potential new drugs.
Commenting on the collaboration, Cyprotex Chief Executive Officer Robert Morrisson Atwater said: "Consistent, high quality compound data is essential for efficient drug discovery because it enables you to predict the potential of new compounds before they've even been synthesised. In order to develop better drugs faster, the industry needs to start with compounds that have the best potential to succeed as drugs. Without the ability to effectively predict how compounds will behave in the body, pharmaceutical companies have to perform time and cost-consuming iterations of design and synthesis. Cyprotex's high capacity ADME screening system, Cloe Screen™ will ensure that we have a good basis from which to build predictive models, a capability that we can add to our existing service offerings to enable our Pharmaceutical and Biotechnology partners to improve the efficiency of their drug discovery."
Dr. Gareth Jenkins, Peakdale's Business Development Manager, added: "We are delighted to enter into this collaboration which will enable Peakdale to combine pharmacology knowledge with our innovative chemistry skills as part of the process we use to design new compounds for our growing customer base. By working together in this way, all our customers will benefit through more efficient lead optimisation and the identification of better drug candidates."
For further information:
Robert Morrisson Atwater, Chief Executive Officer
Cyprotex plc
Tel: +44 (0) 1625 505152
ir@cyprotex.com
www.cyprotex.com
Gareth Jenkins, Business Development Manager
Peakdale Molecular Limited
Tel: +44 (0) 1298 816700
gareth.jenkins@peakdale.co.uk
www.peakdale.com
Henry Harrison-Topham / Heather Salmond
Bankside Consultants Limited
Tel: +44 (0) 20 7444 4140
henry.ht@bankside.com
www.bankside.com
